Tag: VIVA 2025

In this issue: CREST-2 analysis: Experts focus on medical management, trial design and plaque imaging following the presentation of landmark trial data Opinion: Vascular Society...

In this issue: CREST-2 analysis: Experts focus on medical management, trial design and plaque imaging following the presentation of landmark trial data Opinion: Vascular...

A focused session at the 2025 Vascular Interventional Advances (VIVA) conference (2–5 November, Las Vegas, USA) homed in on the latest findings from the...

Results at 12 months from the FORWARD PAD investigational device exemption (IDE) and feasibility studies demonstrate low rates of major amputation and cardiovascular death...

One-year outcomes in the ROADSTER 3 post-approval study to evaluate the safety and effectiveness of transcarotid artery revascularisation (TCAR) using the Enroute stent and...

Thirty-day results from the PERFORMANCE III study of integrated embolic protection (IEP) in transcarotid artery revascularisation (TCAR) demonstrate "very low" 30-day event rates. Sean...

DISRUPT BTK II results out to 12 months demonstrate the strong safety profile and consistent effectiveness of the Shockwave peripheral intravascular lithotripsy (IVL) system...

Full results from the ENGULF pivotal study of the Hēlo thrombectomy system (Endovascular Engineering) in acute intermediate risk pulmonary embolism (PE) patients demonstrated a...

Three-year data from the LIFE-BTK randomised controlled trial, presented today at the 2025 Vascular Interventional Advances (VIVA) conference (2–5 November, Las Vegas, USA), demonstrate the...

Mechanical thrombectomy by means of computer-assisted vacuum thrombectomy (CAVT) using the 16Fr Lightning Flash system (Penumbra) along with anticoagulation for acute-to-intermediate pulmonary embolism (PE)...

Surmodics has announced that results from a sex-specific analysis of 160 real-world acute, subacute, and chronic thrombotic limb ischaemia patients from its PROWL registry...